Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20355)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | GR50 | GRmax | GR_AOC | GEC50 | GRinf | GR Hill Coefficient | GR r2 | pval_GR |
|---|---|---|---|---|---|---|---|---|---|
| BT-549 | RO-3306 | -inf | -0.1143 | ||||||
| SK-BR-3 | BMS-265246 | -inf | 0.0240 | ||||||
| HCC1954 | BMS-265246 | -inf | -0.1012 | ||||||
| HCC1500 | THZ531 | -inf | -0.9990 | ||||||
| HCC1500 | THZ1 | -inf | -0.9999 | ||||||
| HCC1500 | SHP099 | -inf | -0.1868 | ||||||
| MDA-MB-134-VI | Alvocidib | -inf | -0.4621 | ||||||
| MDA-MB-134-VI | GSK2334470 | -inf | 0.1440 | ||||||
| HCC1500 | Senexin B | -inf | -0.9794 | ||||||
| HCC1419 | LY3023414 | -inf | -0.6005 | ||||||
| HCC1419 | AZD6738 | -inf | 0.3243 | ||||||
| HCC1500 | RO-3306 | -inf | -0.9896 | ||||||
| MDA-MB-134-VI | SHP099 | -inf | 0.8081 | ||||||
| HCC1500 | GSK2334470 | -inf | -0.7194 | ||||||
| HCC1500 | Alvocidib | -inf | -0.9990 | ||||||
| MDA-MB-134-VI | RO-3306 | -inf | 0.0360 | ||||||
| HCC1500 | Ulixertinib | -inf | 0.3396 | ||||||
| MCF 10A | Alvocidib | -inf | -0.7589 | ||||||
| HCC1500 | AZD6738 | -inf | -0.9469 |